Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acomplia in abdominally obese patients with cardiovascular risk factors
NCT00263042Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Dec 2005
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 43
01
Overview
Phase 3, randomised, double-blind trial of rimonabant in cardiovascular disease (CVD), sponsored by Sanofi. Primary endpoint: Major Adverse Cardiovascular Events at 50 months. Started Dec 2005; status: terminated.
02
Drugs
rimonabant
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT00263042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263042.